Harmony Biosciences Holdings, Inc.2024财年第三财季实现净利润46.09百万美元，同比增加19.84%

市场透视11-03

11月3日，Harmony Biosciences Holdings, Inc.（HRMY.US）公布财报，公告显示公司2024财年第三财季净利润为46.09百万美元，同比增加19.84%；其中营业收入为1.86亿美元，同比增加16.25%，每股基本收益为0.81美元。从资产负债表来看，Harmony Biosciences Holdings, Inc.（HRMY.US）总负债3.31亿美元，其中...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2480758968?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-03 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2480758968","market":"us","top_or_hot":-1,"title":"Harmony Biosciences Holdings, Inc.2024财年第三财季实现净利润46.09百万美元，同比增加19.84%","media":"市场透视","content":"<div>\n<p>11月3日，Harmony Biosciences Holdings, Inc.（HRMY.US）公布财报，公告显示公司2024财年第三财季净利润为46.09百万美元，同比增加19.84%；其中营业收入为1.86亿美元，同比增加16.25%，每股基本收益为0.81美元。从资产负债表来看，Harmony Biosciences Holdings, Inc.（HRMY.US）总负债3.31亿美元，其中...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000206ab98f56c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harmony Biosciences Holdings, Inc.2024财年第三财季实现净利润46.09百万美元，同比增加19.84%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarmony Biosciences Holdings, Inc.2024财年第三财季实现净利润46.09百万美元，同比增加19.84%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-03 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000206ab98f56c&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月3日，Harmony Biosciences Holdings, Inc.（HRMY.US）公布财报，公告显示公司2024财年第三财季净利润为46.09百万美元，同比增加19.84%；其中营业收入为1.86亿美元，同比增加16.25%，每股基本收益为0.81美元。从资产负债表来看，Harmony Biosciences Holdings, Inc.（HRMY.US）总负债3.31亿美元，其中...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000206ab98f56c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HRMY","symbol_name":"Harmony Biosciences Holdings, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000206ab98f56c&s=b","article_id":"2480758968","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000206ab98f56c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2480758968","pubTimestamp":1730563278,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月3日，Harmony Biosciences Holdings, Inc.公布财报，公告显示公司2024财年第三财季净利润为46.09百万美元，同比增加19.84%；其中营业收入为1.86亿美元，同比增加16.25%，每股基本收益为0.81美元。机构评级：截至2024年11月3日，当前有9家机构对Harmony Biosciences Holdings, Inc.目标价做出预测，其中目标均价为47.11美元，其中最低目标价为28.00美元，最高目标价为59.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"HRMY":"Harmony Biosciences Holdings, Inc."},"translate_title":"Harmony Biosciences Holdings, Inc. achieved a net profit of US $46.09 million in the third fiscal quarter of fiscal year 2024, a year-on-year increase of 19.84%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRMY":1},"content_text":"11月3日，Harmony Biosciences Holdings, Inc.（HRMY.US）公布财报，公告显示公司2024财年第三财季净利润为46.09百万美元，同比增加19.84%；其中营业收入为1.86亿美元，同比增加16.25%，每股基本收益为0.81美元。从资产负债表来看，Harmony Biosciences Holdings, Inc.（HRMY.US）总负债3.31亿美元，其中短期债务56.83百万美元，资产负债比为2.81，流动比率为3.25。机构评级：截至2024年11月3日，当前有9家机构对Harmony Biosciences Holdings, Inc.目标价做出预测，其中目标均价为47.11美元，其中最低目标价为28.00美元，最高目标价为59.00美元。公司简介：Harmony Biosciences Holdings Inc是一家商业阶段的制药公司，致力于为患有罕见的神经系统疾病且未满足医疗需求的患者开发和商业化创新疗法。该公司的产品WAKIX (pitolisant)是一种具有新颖作用机制的分子，专门设计通过与H3受体结合来增加大脑中组胺信号，用于治疗发作性睡眠的成年患者猝厥。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480758968"}